MacroGenics, Inc. (NASDAQ:MGNX) Receives $7.63 Average PT from Brokerages

Shares of MacroGenics, Inc. (NASDAQ:MGNX - Get Free Report) have received a consensus recommendation of "Hold" from the eleven analysts that are currently covering the firm, MarketBeat.com reports. Eight investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $7.63.

A number of research analysts have recently issued reports on MGNX shares. Evercore ISI raised MacroGenics to a "strong-buy" rating in a research note on Monday, September 16th. JMP Securities cut MacroGenics from an "outperform" rating to a "market perform" rating in a report on Thursday, November 7th. HC Wainwright reaffirmed a "neutral" rating and issued a $4.00 price target on shares of MacroGenics in a research note on Wednesday, November 6th. Finally, StockNews.com raised MacroGenics from a "sell" rating to a "buy" rating in a research note on Sunday, November 10th.

MacroGenics Stock Down 1.8 %

NASDAQ:MGNX traded down $0.06 during midday trading on Thursday, hitting $3.35. The company had a trading volume of 472,140 shares, compared to its average volume of 465,508. The company has a market capitalization of $210.26 million, a PE ratio of -2.12 and a beta of 2.04. MacroGenics has a 52-week low of $2.95 and a 52-week high of $21.88. The stock's fifty day moving average price is $3.50 and its 200-day moving average price is $3.74.

Institutional Investors Weigh In On MacroGenics

A number of large investors have recently modified their holdings of MGNX. XTX Topco Ltd purchased a new stake in MacroGenics in the third quarter worth about $37,000. China Universal Asset Management Co. Ltd. raised its position in shares of MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company's stock worth $40,000 after acquiring an additional 4,707 shares in the last quarter. SG Americas Securities LLC purchased a new position in shares of MacroGenics in the 3rd quarter valued at approximately $55,000. DRW Securities LLC bought a new stake in shares of MacroGenics during the second quarter valued at approximately $56,000. Finally, XML Financial LLC grew its stake in MacroGenics by 66.0% in the third quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company's stock worth $58,000 after purchasing an additional 7,000 shares during the period. Institutional investors own 96.89% of the company's stock.

MacroGenics Company Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.